Tigecycline Dosing for CRAB in Child-Pugh C Cirrhosis
For a patient with decompensated cirrhosis (Child-Pugh C) and CRAB infection, use tigecycline 100 mg loading dose followed by 25 mg every 12 hours, always in combination with another active agent.
FDA-Mandated Dose Reduction
The FDA drug label explicitly requires dose reduction in Child-Pugh C patients 1. After the standard 100 mg loading dose, the maintenance dose must be reduced to 25 mg every 12 hours (half the standard 50 mg dose). This is the only FDA-approved dosing adjustment for any patient population and takes precedence over all other considerations.
Critical Context: High-Dose Tigecycline and Liver Disease
While high-dose tigecycline (200 mg loading, then 100 mg q12h) has been used successfully for severe CRAB infections in ICU patients 2, 3, this approach is contraindicated in Child-Pugh C patients. Recent evidence demonstrates that:
- Standard-dose tigecycline (50 mg q12h) achieved superior outcomes compared to high-dose in liver failure patients, with better microbial eradication and fewer adverse events 4
- High-dose tigecycline in Child-Pugh C patients increased mortality risk (HR 1.85) and caused significantly more hepatotoxicity, coagulopathy, and thrombocytopenia 4
- The reduced dose (25 mg q12h) in Child-Pugh C patients produces AUC exposures equivalent to high-dose tigecycline in non-cirrhotic patients 5
Common pitfall: Attempting to use high-dose tigecycline for severe CRAB infection in cirrhotic patients. The pharmacokinetic data clearly show that tigecycline clearance is already profoundly reduced in critically ill patients with liver disease (8.6 L/h vs normal 21-24 L/h) 5. The 25 mg q12h dose in Child-Pugh C achieves therapeutic exposures without excessive toxicity.
Mandatory Combination Therapy
Tigecycline must never be used as monotherapy for CRAB infections 2. The 2015 ICU Task Force guidelines explicitly state: "Due to the uncertainties about the efficacy of tigecycline in non-approved indications, we recommend its use in combination with another active agent, if possible" 2.
Preferred combination partners (if susceptible):
- Polymyxin B (1.5-3 mg/kg/day; no dose adjustment needed for liver disease) 2
- Sulbactam (9-12 g/day if MIC ≤4 mg/L; may be preferable to preserve polymyxins) 2
- Colistin (loading dose 6-9 million IU, then 4.5 million IU q12h, adjusted for renal function) 2
Infection Site Considerations
Tigecycline has poor serum concentrations and should be avoided for CRAB bacteremia 2. It achieves adequate tissue penetration for:
- Complicated intra-abdominal infections (FDA-approved indication) 1
- Complicated skin/soft tissue infections (FDA-approved indication) 1
- Pneumonia (off-label, requires combination therapy) 2
For CRAB pneumonia specifically: Even with dose reduction, tigecycline can be effective when combined with another active agent, as the MIC threshold of ≤1 mg/L remains achievable 2. However, clinical success depends heavily on source control and overall disease severity rather than drug exposure alone 5.
Monitoring Requirements
Patients with Child-Pugh C receiving tigecycline require:
- Close monitoring for treatment response (clinical improvement should be evident within 7 days) 4
- Surveillance for hepatotoxicity (transaminases, bilirubin)
- Coagulation parameters (fibrinogen, PT/INR)
- Platelet counts
- Renal function (tigecycline can cause azotemia)
Duration: 7-14 days for pneumonia, 5-14 days for intra-abdominal or skin infections, guided by clinical response 1.
When Tigecycline May Not Be Appropriate
Consider alternative agents first if available:
- Sulbactam-durlobactam (if susceptible and available) 6
- Cefiderocol (if susceptible) 6
- Polymyxin-based combinations without tigecycline 7
The 2022 Taiwan guidelines note that tigecycline for CRE (not specifically CRAB) uses standard dosing of 100 mg loading then 50 mg q12h 8, but these recommendations do not address Child-Pugh C patients where FDA labeling mandates dose reduction.